Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Selective Modulation of Gamma-Secretase May Reverse Alzheimer's Disease

By BiotechDaily International staff writers
Posted on 22 Aug 2013
Image: Enzymes act on the APP (Amyloid precursor protein) and cut it into fragments of protein, one of which is called beta-amyloid, which is crucial in the formation of senile plaques in Alzheimer's disease (Photo courtesy of Wikimedia Commons).
Image: Enzymes act on the APP (Amyloid precursor protein) and cut it into fragments of protein, one of which is called beta-amyloid, which is crucial in the formation of senile plaques in Alzheimer's disease (Photo courtesy of Wikimedia Commons).
A new generation of drugs for treatment of Alzheimer's disease (AD) will prevent formation of amyloid-beta peptide-42 (A-beta42), the accumulation of which is considered by many researchers to be the cause of the disease.

In most forms of AD, abnormally large quantities of the long amyloid peptide-42 are formed due to the inappropriate action of the cleavage enzyme gamma-secretase. Gamma-secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma-secretase is amyloid precursor protein (APP), a large integral membrane protein that, when cleaved by both gamma-and beta-secretase, produces a short 39–42 amino acid peptide called amyloid-beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma-secretase is also critical in the related processing of the Notch protein.

Investigators at the Ecole Polytechnique Fédérale de Lausanne (Switzerland) studied a particularly aggressive early-onset type of familial Alzheimer’s disease that appears as early as thirty years of age and leaves patients with a life expectancy of only a few years.

They reported in the August 2, 2013, online edition of the journal Nature Communications that this syndrome was caused by mutations in the transmembrane domain of APP that affected both gamma- and epsilon-cleavage sites, by raising the A-beta42/40 ratio. The longer A-beta42 peptide is the form that aggregates into toxic amyloid plaques.

New drugs now under development change the location where gamma secretase cleaves the APP protein, thus producing amyloid peptide 38 instead of 42, which is shorter and does not aggregate into plaques.

"Scientists have been trying to target gamma secretase to treat Alzheimer's for over a decade," said senior author Dr. Patrick Fraering, professor of neurosciences at the Ecole Polytechnique Fédérale de Lausanne. "Our work suggests that next-generation molecules, by modulating rather than inhibiting the enzyme, could have few, if any, side-effects. It is tremendously encouraging."

Related Links:

Ecole Polytechnique Fédérale de Lausanne



Channels

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.